Starling Oncology Warrant
STLNW
12 hedge funds and large institutions have $707K invested in Starling Oncology Warrant in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
47% more capital invested
Capital invested by funds: $479K → $707K (+$227K)
9% more funds holding
Funds holding: 11 → 12 (+1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$11.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$816 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$10 |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$10 |
STLNW Hedge Fund Activity: Q2 2026 in Review
12 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Warrant (STLNW) for Q2 2026, worth a combined $707K — up 47% from $479K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new STLNW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Wolverine Asset Management, adding an estimated $11.1K. The largest seller was Clear Street, cutting an estimated $10.
- 12 institutional investors held Starling Oncology Warrant (STLNW) as of Q2 2026, up from 11 in Q1 2026.
- Funds reported $707K of Starling Oncology Warrant stock for Q2 2026, up 47% quarter-over-quarter.
- 1 fund opened new Starling Oncology Warrant positions in Q2 2026 and 0 closed out, a net change of +1 holder.
- The largest Starling Oncology Warrant buyer in Q2 2026 was Wolverine Asset Management, an estimated $11.1K added.
- The largest Starling Oncology Warrant seller in Q2 2026 was Clear Street, an estimated $10 sold.
Based on aggregated 13F filings for Q2 2026.